COMPANY OVERVIEW

Finding a Cure to Leading and Most Serious Causes of Blindness

Alkeus Pharmaceuticals is a clinical stage biotechnology company focused on ophthalmic conditions with limited treatment options. Building on years of groundbreaking research in ophthalmology and on well-understood and validated biochemical processes, Alkeus has combined this knowledge to bring therapies from bench to bedside.

Alkeus most advanced therapeutic program is based on new compounds that mainly target dry age-related macular degeneration (dry AMD) and Stargardt's disease, the two leading causes of blindness in patients over 50 (AMD) and in teenagers (Stargardt). These compounds have shown significant promise by reducing the accumulation of toxic piments in the eye which resulted in preserved vision in different mouse models.
In particular, Alkeus' lead compound, ALK-001, was specifically designed to treat Stargardt's disease and has demonstrated safety and efficacy in mice.

Alkeus is also investigating new methods to treat Leber Hereditary Optic Neuropathy (LHON), an inherited disease that leads to blindness in young adults as well as autosomal recessive Retinitis Pigmentosa.

The company is preparing clinical trials for patients with the late form of dry-AMD (also known as Geographic Atrophy) and for patients with Stargardt's disease.